Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Tools & Technology › Sequencing › Ignyta to Seek Entrectinib Approval in ROS1-Positive Lung Cancer, Tissue-Agnostic Indication

Ignyta to Seek Entrectinib Approval in ROS1-Positive Lung Cancer, Tissue-Agnostic Indication

Sep 12, 2017
|
Turna Ray
Premium

NEW YORK (GenomeWeb) – Next year, precision medicine company Ignyta will submit two applications for its lead therapeutic product entrectinib — one in ROS1-positive non-small cell lung cancer, and another for patients with any kind of solid tumor characterized by NTRK-fusions.

Ignyta not only plans to garner near concurrent review and approval entrectinib for the two indications, but also aims to introduce a multimarker NGS-based companion diagnostic on the market alongside the drug, which can identify patients who have these biomarkers and are most likely to respond.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
23
Featured Webinar

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar
25
Featured Webinar

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

Apr
08
Featured Webinar

Interpretation of Comprehensive Genomic Profiling from ctDNA Through Clinical Decision Support

Sponsored by
Roche

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.

What's Popular?

In Molecular Diagnostics

  1. Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year

    Premium

  2. FDA Approves Regeneron, Sanofi's Libtayo With Agilent PD-L1 CDx in Frontline NSCLC

  3. Personal Genome Diagnostics to Build Commercial Infrastructure, Drive Partnerships With New Funding

    Premium

  4. Qiagen, Inovio Expand CDx Partnership, Starting With NGS Test for Cervical Dysplasia Therapy

  5. Biocept, Protean BioDiagnostics Team up to Study EGFR Assay in Lung Cancer

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.